JP2004509953A5 - - Google Patents

Download PDF

Info

Publication number
JP2004509953A5
JP2004509953A5 JP2002531107A JP2002531107A JP2004509953A5 JP 2004509953 A5 JP2004509953 A5 JP 2004509953A5 JP 2002531107 A JP2002531107 A JP 2002531107A JP 2002531107 A JP2002531107 A JP 2002531107A JP 2004509953 A5 JP2004509953 A5 JP 2004509953A5
Authority
JP
Japan
Prior art keywords
methyl
morpholin
dichlorobenzyl
urea
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002531107A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004509953A (ja
JP5069392B2 (ja
Filing date
Publication date
Priority claimed from GB0023973A external-priority patent/GB0023973D0/en
Priority claimed from GB0107643A external-priority patent/GB0107643D0/en
Application filed filed Critical
Priority claimed from PCT/GB2001/004350 external-priority patent/WO2002026723A1/en
Publication of JP2004509953A publication Critical patent/JP2004509953A/ja
Publication of JP2004509953A5 publication Critical patent/JP2004509953A5/ja
Application granted granted Critical
Publication of JP5069392B2 publication Critical patent/JP5069392B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2002531107A 2000-09-29 2001-09-28 炎症性疾患の処置に有用な化合物 Expired - Lifetime JP5069392B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0023973A GB0023973D0 (en) 2000-09-29 2000-09-29 Therapeutically useful compounds
GB0023973.1 2000-09-29
GB0107643A GB0107643D0 (en) 2001-03-27 2001-03-27 Therapeutically useful compounds
GB0107643.9 2001-03-27
PCT/GB2001/004350 WO2002026723A1 (en) 2000-09-29 2001-09-28 Compounds useful in the treatment of inflammatory diseases

Publications (3)

Publication Number Publication Date
JP2004509953A JP2004509953A (ja) 2004-04-02
JP2004509953A5 true JP2004509953A5 (enExample) 2008-11-13
JP5069392B2 JP5069392B2 (ja) 2012-11-07

Family

ID=26245081

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002531107A Expired - Lifetime JP5069392B2 (ja) 2000-09-29 2001-09-28 炎症性疾患の処置に有用な化合物

Country Status (20)

Country Link
US (1) US7157457B2 (enExample)
EP (2) EP1586567A1 (enExample)
JP (1) JP5069392B2 (enExample)
KR (1) KR20030040510A (enExample)
CN (1) CN1478084A (enExample)
AR (1) AR037080A1 (enExample)
AT (1) ATE345331T1 (enExample)
AU (1) AU2001290146A1 (enExample)
BR (1) BR0114321A (enExample)
CA (1) CA2423305A1 (enExample)
CZ (1) CZ20031194A3 (enExample)
DE (1) DE60124576T2 (enExample)
ES (1) ES2275729T3 (enExample)
HU (1) HUP0303107A2 (enExample)
IL (1) IL155092A0 (enExample)
MX (1) MXPA03002813A (enExample)
NO (1) NO20031443L (enExample)
NZ (1) NZ525055A (enExample)
PL (1) PL362984A1 (enExample)
WO (1) WO2002026723A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0207450D0 (en) * 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
SI1305329T2 (sl) 2000-08-05 2015-07-31 Glaxo Group Limited S-fluorometil ester 6alfa,9alfa-difluoro-17alfa-(2-furanilkarboksil)oksi-11beta-hidroksi- 16alfa-metil-3-okso-androst-1,4-dien-17-karbotiojske kisline kot protivnetno sredstvo
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
CA2445839A1 (en) 2001-04-30 2002-11-07 Glaxo Group Limited Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha
GB0207432D0 (en) * 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
GB0207449D0 (en) * 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
GB0207439D0 (en) * 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
GB0207447D0 (en) * 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
TW200400035A (en) 2002-03-28 2004-01-01 Glaxo Group Ltd Novel compounds
GB0207436D0 (en) * 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
GB0211759D0 (en) * 2002-05-22 2002-07-03 Glaxo Group Ltd Novel compounds
GB0212357D0 (en) * 2002-05-29 2002-07-10 Glaxo Group Ltd Novel compounds
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US6919356B2 (en) 2002-09-26 2005-07-19 Bristol Myers Squibb Company N-substituted heterocyclic amines as modulators of chemokine receptor activity
DE60329831D1 (de) * 2003-06-10 2009-12-10 Biondi Ricardo Miguel Verwendung einer Verbingung gemäss Formel I zur Herstellung einer pharmazeutischen Zubereitung
RU2387646C2 (ru) 2003-08-29 2010-04-27 Рэнбакси Лабораториз Лимитед Ингибиторы фосфодиэстеразы типа-iv
KR101011848B1 (ko) 2004-09-08 2011-02-01 미쓰비시 타나베 파마 코퍼레이션 모르폴린 화합물
EP1992628A1 (en) 2007-05-18 2008-11-19 Glaxo Group Limited Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones
US20080207659A1 (en) 2007-02-15 2008-08-28 Asit Kumar Chakraborti Inhibitors of phosphodiesterase type 4
CN101679258A (zh) * 2007-03-13 2010-03-24 亚瑞特医疗公司 作为可溶性环氧化合物水解酶抑制剂的4-哌啶基脲化合物
JP5313881B2 (ja) 2007-04-04 2013-10-09 興和株式会社 テトラヒドロイソキノリン化合物
BRPI0819989A2 (pt) 2007-12-05 2015-05-12 Biovitrum Ab Publ Composto, formulação farmacêutica, uso de um composto, processo para a preparação de um composto, e, métodos para tratamento ou prevenção de condições ou doênças e para inibição da angiogênese
KR20100096222A (ko) 2007-12-05 2010-09-01 아스트라제네카 아베 피페라진 유도체 및 렙틴 수용체 조절물질로서 그 유도체의 용도
RU2014126070A (ru) 2011-12-01 2016-01-27 Глэксо Груп Лимитед Способы лечения и предотвращения глазных заболеваний
FR3022142B1 (fr) 2014-06-16 2019-07-12 Universite Paul Sabatier - Toulouse Iii Inhibition de la chimiokine ccl7 ou de son recepteur ccr3 pour le traitement et le diagnostic du cancer de la prostate
AU2015304847B2 (en) 2014-08-22 2018-10-25 Glaxosmithkline Intellectual Property Development Limited Tricyclic nitrogen containing compounds for treating Neisseria gonorrhoea infection
EP3570893A1 (en) 2017-01-17 2019-11-27 GlaxoSmithKline Intellectual Property Development Ltd Non peptidic heterobivalent molecules for treating inflammatory diseases
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法
CN111269340B (zh) * 2020-03-31 2020-12-29 台州学院 一种以1-甲烷磺酰哌嗪为配体的螯合树脂及其制备方法和应用
CN120132049B (zh) * 2025-03-05 2025-08-26 西南医科大学附属口腔医院 茶多酚涂层改性的3d打印掺锶羟基磷灰石复合支架的制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3087763B2 (ja) * 1990-11-30 2000-09-11 三井化学株式会社 新規な複素環式化合物およびそれを含有する医薬組成物
JPH04247074A (ja) * 1991-02-01 1992-09-03 Yoshitomi Pharmaceut Ind Ltd 4−モルホリノ安息香酸誘導体の製造法
JPH04270272A (ja) * 1991-02-25 1992-09-25 Yoshitomi Pharmaceut Ind Ltd アミノアルキルモルホリン誘導体の製造法
US5753654A (en) * 1994-05-18 1998-05-19 Nisshin Flour Milling Co., Ltd. Diaminomethylidene derivatives
WO1995031431A1 (en) * 1994-05-18 1995-11-23 Nisshin Flour Milling Co., Ltd. Novel diaminomethylidene derivative
DK1174431T3 (da) * 1997-11-12 2012-08-20 Bayer Pharma AG 2-phenyl-substitueret imidazo triazinon som phoshodiesterase-inhibitorer
JP3593037B2 (ja) * 1998-11-20 2004-11-24 エフ.ホフマン−ラ ロシュ アーゲー ピロリジン誘導体ccr−3受容体アンタゴニスト
CA2347769A1 (en) * 1998-12-18 2000-06-22 Dean A. Wacker 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity
CA2346933A1 (en) 1998-12-18 2000-06-22 Dupont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity

Similar Documents

Publication Publication Date Title
JP2004509953A5 (enExample)
JP2004509952A5 (enExample)
JP2002540204A5 (enExample)
JP2013506637A5 (enExample)
JP2006505522A5 (enExample)
JP2007516173A5 (enExample)
JP2004517080A5 (enExample)
JP2013517283A5 (enExample)
CA2396824A1 (en) Heteroaromatic carboxamide derivatives and their use as inhibitors of the enzyme ikk-2
JP2009221205A5 (enExample)
EP1411932A1 (de) Kombinationstherapie substituierter oxazolidinone
WO2008130021A2 (en) Heterocyclic hydrazide compound and pesticidal use of the same
JP2005538100A (ja) I.A.慢性関節リウマチの治療においてp38キナーゼ阻害剤として使用される縮合ヘテロアリール誘導体
RU2002132385A (ru) Новые соединения
WO2000047194A2 (en) METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR
JP2004507461A5 (enExample)
JP2002506858A (ja) Cmv感染症の治療に有用な1,3,4−チアジアゾール
RU2008141510A (ru) Новые соединения
JP2008519761A5 (enExample)
JP2006503081A5 (enExample)
JP2004523490A5 (enExample)
RU2012117885A (ru) 2,3,5-тризамещенные пирролы, фармацевтическая композиция и лекарственное средство (варианты) на их основе, способ получения соединений (варианты)
RU2011116232A (ru) Пиразолопиридиновые производные как ингибиторы надфн-оксидазы
ZA200508623B (en) Use of derivatives of 2,4-dihydro-[1,2,4]triazole-3-thione as inhibitors of the enzyme myeloperoxidase (MPO)
JP2008502614A5 (enExample)